Roivant Sciences Ltd. $ROIV Stock Holdings Lifted by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC grew its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 64.7% in the 1st quarter, HoldingsChannel reports. The firm owned 2,800,000 shares of the company’s stock after buying an additional 1,100,000 shares during the quarter. Roivant Sciences comprises approximately 4.0% of Affinity Asset Advisors LLC’s holdings, making the stock its 5th largest holding. Affinity Asset Advisors LLC’s holdings in Roivant Sciences were worth $77,560,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Pictet Asset Management Holding SA grew its stake in Roivant Sciences by 790.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company’s stock valued at $50,180,000 after purchasing an additional 2,052,693 shares during the last quarter. Capricorn Fund Managers Ltd lifted its position in shares of Roivant Sciences by 124.4% during the fourth quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock valued at $9,667,000 after buying an additional 247,000 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Roivant Sciences by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after buying an additional 3,254,113 shares during the last quarter. Exchange Traded Concepts LLC bought a new stake in shares of Roivant Sciences in the 4th quarter valued at about $5,435,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in shares of Roivant Sciences by 90.9% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 80,561 shares of the company’s stock valued at $1,746,000 after buying an additional 38,354 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Price Performance

NASDAQ:ROIV opened at $35.01 on Friday. The company’s fifty day moving average price is $32.24 and its 200-day moving average price is $28.62. Roivant Sciences Ltd. has a 1-year low of $10.90 and a 1-year high of $37.00. The firm has a market capitalization of $25.18 billion, a P/E ratio of -58.35 and a beta of 1.11.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, Director Daniel Allen Gold sold 12,380 shares of Roivant Sciences stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total transaction of $436,766.40. Following the completion of the transaction, the director owned 13,689,166 shares in the company, valued at approximately $482,953,776.48. This trade represents a 0.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Melissa B. Epperly sold 17,750 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $34.38, for a total value of $610,245.00. Following the completion of the sale, the director owned 16,474 shares in the company, valued at $566,376.12. The trade was a 51.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,855,913 shares of company stock valued at $62,649,633. 10.80% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Weiss Ratings lowered shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price target on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Guggenheim increased their price objective on Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.59.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.